BeOne Medicines Ltd. (ONC)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: Switzerland
Exchange: NASDAQ
Market cap: $266.59B
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.
Latest financial period: June 30, 2026
Filed with the SEC: August 5, 2026
Estimated earnings date: November 5, 2026
Profit #133 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROIC | 30.6% | 21.8% | 7.2% | |
Growth #61 of 1484 companies
Payout #1117 of 1484 companies
Safety #587 of 1484 companies
Price #1300 of 1484 companies
